Lennert’s lymphoma - a diagnostic dilemma: a case report and pathologic review of literature

Akhil Kapoor, Surender Beniwal, Ramesh Purohit, Vanita Kumar, Harvindra Singh Kumar


Lymphoepitheloid lymphoma, also referred to as Lennert’s lymphoma is a T-cell lymphoma characterized by the massive proliferation of epithelial cell clusters infiltrating normal lymph nodal architecture along with lymphoid cells. Epithelial cells can also be associated with infectious lymphadenopathy and Hodgkin’s lymphoma. This presents a diagnostic dilemma. We present a case of Lennert’s lymphoma along with review of literature with special emphasis on morphological features and immmunohistochemistry findings.


Lymphoepitheloid lymphoma, Lennert’s lymphoma, Epithelioid cell

Full Text:



Aboud KA, Aboud DA. Eponyms in the literature of cutaneous lymphomas. Our Dermatol Online. 2013;4(3):385-8.

Lennert K, Mohri N, Stein H, Kaiserling E. The histopathology of malignant lymphoma. Br J Haematol. 1975;31(Suppl):193-203.

Feller AC, Griesser GH, Mak TW, Lennert K. Lymphoepithelioid lymphoma (Lennert’s lymphoma) is a monoclonal proliferation of helper/inducer T cells. Blood. 1986;68:663-7.

Patsouris E, Engelhard M, Zwingers T, Lennert K. Lymphoepithelioid cell lymphoma (Lennert’s lymphoma): clinical features derived from analysis of 108 cases. Br J Haematol. 1993;84:346-8.

Lennert K, Mestdagh J. Hodgkin’s disease with constantly high content of epithelioid cells. Virchows Arch A Pathol Pathol Anat. 1968;344:1-20.

Banks PM. The distinction of Hodgkin’s disease from T cell lymphoma. Semin Diagn Pathol. 1992;9:279-83.

Patsouris E, Handennert N. Cytohistologic and immunohistochemical findings in Hodgkin’s disease, mixed cellularity type, with a high content of epithelioid cells. Am J Surg Pathol. 1989;13(12):1014-22.

Butler JJ. The histologic diagnosis of Hodgkin’s disease. Semin Diagn Pathol. 1992;9:252.

Osborne BM, Uthman MO, Butler JJ, McLaughlin P. Differentiation of T-cell lymphoma from Hodgkin’s disease: mitotic rate and S-phase analysis. Am J Clin Pathol. 1990;93:227.

Yamashita Y, Nakamura S, Kagami Y, Hasegawa Y, Kojima H, Nagasawa T, et al. Lennert’s lymphoma: a variant of cytotoxic T-cell lymphoma? Am J Surg Pathol. 2000;24:1627-33.

Gerdes I, Lemke H, Baisch H, Wacker HH, Schwab U. Stein cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Immunology. 1984;133:1710.

Knowles DM. Neoplastic Hematopathology. In: Knowles DM, eds. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2001: 530-531. Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2005;363:271-3.

Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood. 1997;89:4514-20.

Gisselbrecht C, Gaulard P, Lepage E, Coiffier B. Prognostic significance of T-Cell phenotype in aggressive non-Hodgkin’s lymphomas, for the groupe d’Etudes des lymphomes de l’adulte (GELA). Blood. 1998;92:76-82.

Geissinger E, Odenwald T, Lee SS, Bonzheim I, Roth S, Reimer P, et al. Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells. Virchows Arch. 2004;445(4):334-43.

Zeitlinger MA, Schmidinger M, Zielinski CC, Chott A, Raderer M. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab. Leuk Lymphoma. 2005;46:771-4.

D’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093-9.